Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area
- Affiliated Author(s)
- 김진희
- Alternative Author(s)
- Kim, Jin Hee
- Journal Title
- Liver International
- ISSN
- 1478-3223
- Issued Date
- 2017
- Keyword
- combined modality therapy; hepatocellular carcinoma; radiotherapy; radiotherapy dosage; portal vein tumour thrombosis
- Abstract
- Background & Aims: This nationwide, multicenter study investigated treatment outcomes as well as the optimal radiother-
apeutic strategy in patients with hepatocellular carcinoma (HCC) and portal vein tumour thrombosis (PVTT). Methods: We
retrospectively reviewed the records of 985 patients who received radiotherapy (RT) for PVTT. The median equivalent RT
dose was 48.75 Gy. Combined treatment, defined as liver-directed treatments performed within a month of RT, was admin-
istered to 657 patients (66.7%). The PVTT and primary tumour were irradiated in 413 patients (41.9%), and PVTT only was
targeted in 572 patients (58.1%).
Results: The response rate of the PVTT was 51.8%, and RT responders had a significantly
longer survival than non-responders (15.2 vs. 6.9 months). Equivalent RT dose and combined treatment predicted response
of PVTT. The median overall survival (OS) was 10.2 months. Multivariate analysis revealed the equivalent RT dose ˃45 Gy
and combined treatment as significant positive factors for OS. In the propensity score matching analysis, the combined treat-
ment group had better OS than the no combined treatment group, whereas the OS of the PVTT + primary tumour group
did not differ significantly from that of the PVTT only group.
Conclusion: The equivalent RT dose ˃45 Gy, given in combi-
nation with other treatments, provided better PVTT control and OS. The optimal RT volume is suggested for either PVTT + primary or PVTT only. Taken together, multimodal treatment with equivalent RT dose higher than 45 Gy is recom-
mended for patients with HCC and PVTT.
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.